Falkai P
Department of Psychiatry, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.
J Clin Psychiatry. 1999;60 Suppl 17:36-40; discussion 46-8.
During the last decade, it became evident that antidepressants may represent a useful treatment option for a variety of primary psychiatric disorders other than depression. Improved understanding of both underlying etiology of these disorders and pharmacologic modes of action of available treatments has led to an improvement in conditions such as panic disorder, generalized anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder, and premenstrual dysphoric disorder. In addition, evidence is accumulating that some new antidepressants may be of therapeutic value in treatment of some subtypes of depressive disorder previously unresponsive to treatment or difficult to treat, such as seasonal affective disorder, depression with atypical features, and recurrent brief depression. Mirtazapine is an antidepressant with mode of action different from other currently available antidepressants. A review of currently available data of mirtazapine's use in indications other than depression and in some types of depressive disorder is presented.
在过去十年中，有一点变得很明显，即抗抑郁药可能是治疗除抑郁症之外的多种原发性精神障碍的一种有效治疗选择。对这些障碍的潜在病因以及现有治疗方法的药理作用方式的更好理解，已使惊恐障碍、广泛性焦虑障碍、强迫症、创伤后应激障碍和经前烦躁障碍等病症的治疗状况得到改善。此外，越来越多的证据表明，一些新型抗抑郁药可能对治疗某些以前对治疗无反应或难以治疗的抑郁症亚型具有治疗价值，例如季节性情感障碍、非典型性抑郁症和复发性短暂抑郁症。米氮平是一种作用方式与目前其他可用抗抑郁药不同的抗抑郁药。本文对米氮平在抑郁症以外的适应症以及某些类型抑郁症中的现有使用数据进行了综述。
